These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29153866)

  • 1. A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
    McRee AJ; Marcom PK; Moore DT; Zamboni WC; Kornblum ZA; Hu Z; Phipps R; Anders CK; Reeder-Hayes K; Carey LA; Weck KE; Perou CM; Dees EC
    Clin Breast Cancer; 2018 Aug; 18(4):289-297. PubMed ID: 29153866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
    Pistilli B; Pluard T; Urruticoechea A; Farci D; Kong A; Bachelot T; Chan S; Han HS; Jerusalem G; Urban P; Robinson D; Mouhaër SL; Tomaso ED; Massacesi C; Saura C
    Breast Cancer Res Treat; 2018 Apr; 168(2):357-364. PubMed ID: 29198055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
    Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
    Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
    Mayer IA; Abramson VG; Isakoff SJ; Forero A; Balko JM; Kuba MG; Sanders ME; Yap JT; Van den Abbeele AD; Li Y; Cantley LC; Winer E; Arteaga CL
    J Clin Oncol; 2014 Apr; 32(12):1202-9. PubMed ID: 24663045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.
    Bedard PL; Tabernero J; Janku F; Wainberg ZA; Paz-Ares L; Vansteenkiste J; Van Cutsem E; Pérez-García J; Stathis A; Britten CD; Le N; Carter K; Demanse D; Csonka D; Peters M; Zubel A; Nauwelaerts H; Sessa C
    Clin Cancer Res; 2015 Feb; 21(4):730-8. PubMed ID: 25500057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
    Rodon J; Braña I; Siu LL; De Jonge MJ; Homji N; Mills D; Di Tomaso E; Sarr C; Trandafir L; Massacesi C; Eskens F; Bendell JC
    Invest New Drugs; 2014 Aug; 32(4):670-81. PubMed ID: 24652201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
    Ando Y; Inada-Inoue M; Mitsuma A; Yoshino T; Ohtsu A; Suenaga N; Sato M; Kakizume T; Robson M; Quadt C; Doi T
    Cancer Sci; 2014 Mar; 105(3):347-53. PubMed ID: 24405565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
    Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).
    Loibl S; de la Pena L; Nekljudova V; Zardavas D; Michiels S; Denkert C; Rezai M; Bermejo B; Untch M; Lee SC; Turri S; Urban P; Kümmel S; Steger G; Gombos A; Lux M; Piccart MJ; Von Minckwitz G; Baselga J; Loi S
    Eur J Cancer; 2017 Nov; 85():133-145. PubMed ID: 28923573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
    Ma CX; Luo J; Naughton M; Ademuyiwa F; Suresh R; Griffith M; Griffith OL; Skidmore ZL; Spies NC; Ramu A; Trani L; Pluard T; Nagaraj G; Thomas S; Guo Z; Hoog J; Han J; Mardis E; Lockhart C; Ellis MJ
    Clin Cancer Res; 2016 Apr; 22(7):1583-91. PubMed ID: 26563128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer.
    Massard C; Chi KN; Castellano D; de Bono J; Gravis G; Dirix L; Machiels JP; Mita A; Mellado B; Turri S; Maier J; Csonka D; Chakravartty A; Fizazi K
    Eur J Cancer; 2017 May; 76():36-44. PubMed ID: 28282611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
    Garrido-Castro AC; Saura C; Barroso-Sousa R; Guo H; Ciruelos E; Bermejo B; Gavilá J; Serra V; Prat A; Paré L; Céliz P; Villagrasa P; Li Y; Savoie J; Xu Z; Arteaga CL; Krop IE; Solit DB; Mills GB; Cantley LC; Winer EP; Lin NU; Rodon J
    Breast Cancer Res; 2020 Nov; 22(1):120. PubMed ID: 33138866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.
    Hyman DM; Snyder AE; Carvajal RD; Gerecitano JF; Voss MH; Ho AL; Konner J; Winkelmann JL; Stasi MA; Monson KR; Iasonos A; Spriggs DR; Bialer P; Lacouture ME; Teitcher JB; Katabi N; Fury MG
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):747-55. PubMed ID: 25672916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
    Smyth LM; Monson KR; Jhaveri K; Drilon A; Li BT; Abida W; Iyer G; Gerecitano JF; Gounder M; Harding JJ; Voss MH; Makker V; Ho AL; Razavi P; Iasonos A; Bialer P; Lacouture ME; Teitcher JB; Erinjeri JP; Katabi N; Fury MG; Hyman DM
    Invest New Drugs; 2017 Dec; 35(6):742-750. PubMed ID: 28281183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study.
    Yang MH; Chen IC; Lu YS
    J Formos Med Assoc; 2019 Sep; 118(9):1333-1338. PubMed ID: 30577988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.
    Saura C; Bendell J; Jerusalem G; Su S; Ru Q; De Buck S; Mills D; Ruquet S; Bosch A; Urruticoechea A; Beck JT; Di Tomaso E; Sternberg DW; Massacesi C; Hirawat S; Dirix L; Baselga J
    Clin Cancer Res; 2014 Apr; 20(7):1935-45. PubMed ID: 24470511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
    Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
    Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits versus risk profile of buparlisib for the treatment of breast cancer.
    Patsouris A; Augereau P; Frenel JS; Robert M; Gourmelon C; Bourbouloux E; Berton-Rigaud D; Chevalier LM; Campone M
    Expert Opin Drug Saf; 2019 Jul; 18(7):553-562. PubMed ID: 31159599
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
    Martín M; Chan A; Dirix L; O'Shaughnessy J; Hegg R; Manikhas A; Shtivelband M; Krivorotko P; Batista López N; Campone M; Ruiz Borrego M; Khan QJ; Beck JT; Ramos Vázquez M; Urban P; Goteti S; Di Tomaso E; Massacesi C; Delaloge S
    Ann Oncol; 2017 Feb; 28(2):313-320. PubMed ID: 27803006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.